Precigen’s Papzimeos, the first FDA-approved immunotherapy for recurrent respiratory papillomatosis, has blockbuster potential in the rare tumor market. However, recent financial disclosures indicate Precigen faces significant budget constraints that may impact commercialization and scalable deployment. The approval marks a milestone for RRP treatment, but the company's fiscal challenges highlight the complexities of bringing novel therapies to market for rare diseases.